New combo therapy aims to tame rare blood vessel disease with fewer steroid side effects

NCT ID NCT05329090

First seen Jun 13, 2026 · Last updated Jun 13, 2026

Summary

This study tested whether adding rituximab to standard steroid treatment helps adults with IgA vasculitis (a rare blood vessel disease) achieve remission without needing long-term steroids. 75 adults with new or relapsing severe disease took part. The goal was to see if the combination allowed patients to stop steroids completely while keeping the disease under control.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for IGA VASCULITIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • APHM de La Timone

    Marseille, 13385, France

  • CHRU Bretonneau

    Tours, 37044, France

  • CHU Clermont Ferrand

    Clermont-Ferrand, 63000, France

  • CHU Clermont Ferrand

    Clermont-Ferrand, 63003, France

  • CHU Marseille

    Marseille, 13005, France

  • CHU Nantes

    Nantes, 44093, France

  • CHU Nîmes (Caremeau)

    Nîmes, 30029, France

  • CHU Strasbourg

    Strasbourg, 67091, France

  • CHU Toulouse

    Toulouse, 31059, France

  • Hopital La Cavale Blanche

    Brest, 29200, France

  • Hôpital André Grégoire

    Montreuil, 93100, France

  • Hôpital Cochin

    Paris, 75679, France

  • Hôpital Edouard Herriot

    Lyon, 69003, France

  • Hôpital Foch

    Suresnes, 92150, France

Conditions

Explore the condition pages connected to this study.